NasdaqCM - Delayed Quote • USD
Compare
At close: 4:00 pm GMT-4
After hours: 5:18 pm GMT-4
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GNPX
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous close
1.5600 - Open
1.5300 - Bid --
- Ask --
- Day's range
1.4400 - 1.5399 - 52-week range
1.4400 - 29.6000 - Volume
26,069 - Avg. Volume
104,196 - Market cap (intra-day)
3.085M - Beta (5Y monthly) -0.51
- PE ratio (TTM)
-- - EPS (TTM)
-18.8100 - Earnings date 21 Aug 2024 - 26 Aug 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
165.00
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
26
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
More about Genprex, Inc.
Recent news: GNPX
View moreAll SEC filings
Corporate changes and voting matters
Periodic financial reports
Proxy statements
Tender offer/acquisition reports
Offering registrations
Performance overview: GNPX
Trailing total returns as of 05/08/2024, which may include dividends or other distributions. Benchmark is
YTD return
GNPX
84.02%
S&P 500
8.73%
1-year return
GNPX
94.87%
S&P 500
15.82%
3-year return
GNPX
98.72%
S&P 500
17.80%
5-year return
GNPX
96.13%
S&P 500
76.88%
Compare to: GNPX
Compare
Select to analyse similar companies using key performance metrics; select up to four stocks.
1.4700
-5.77%
Mkt cap 3.085M
Industry Biotechnology
0.9455
-6.39%
Mkt cap 28.192M
Industry Biotechnology
0.8500
-8.60%
Mkt cap 52.395M
Industry Biotechnology
2.0650
-7.81%
Mkt cap 92.382M
Industry Biotechnology
0.1310
-7.09%
Mkt cap 138.671M
Industry Biotechnology
Mkt cap 116.38M
Industry Biotechnology
1.2900
-3.73%
Mkt cap 68.718M
Industry Biotechnology
4.6000
-2.13%
Mkt cap 188.428M
Industry Biotechnology
3.4600
+2.37%
Mkt cap 23.053M
Industry Biotechnology
0.6355
-8.06%
Mkt cap 22.404M
Industry Biotechnology
0.4880
-4.31%
Mkt cap 500,058
Industry Biotechnology
Statistics: GNPX
View more
Valuation measures
As of 02/08/2024
Market cap
3.29M
Enterprise value
-4.92M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
--
Price/book (mrq)
0.38
Enterprise value/revenue
--
Enterprise value/EBITDA
0.18
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-96.86%
Return on equity (ttm)
-202.83%
Revenue (ttm)
--
Net income avi to common (ttm)
-27.63M
Diluted EPS (ttm)
-18.8100
Balance sheet and cash flow
Total cash (mrq)
8.22M
Total debt/equity (mrq)
--
Levered free cash flow (ttm)
-13.02M
Research analysis: GNPX
View morePeople also watch
DARE Daré Bioscience, Inc.
3.2628
-1.72%
CODX Co-Diagnostics, Inc.
1.0500
-3.67%
COCP Cocrystal Pharma, Inc.
1.7450
-4.64%
AIM AIM ImmunoTech Inc.
0.3226
-8.25%
AYTU Aytu BioPharma, Inc.
2.4300
-3.19%
OPGN OpGen, Inc.
2.5799
-8.84%
VTVT vTv Therapeutics Inc.
14.53
-1.22%
AGRX Agile Therapeutics, Inc.
1.4600
-0.68%
NNVC NanoViricides, Inc.
2.0200
-3.81%
CTXR Citius Pharmaceuticals, Inc.
0.9324
+2.86%
PIXY ShiftPixy, Inc.
1.2100
-12.32%
CAPR Capricor Therapeutics, Inc.
3.7700
-3.08%
CLSD Clearside Biomedical, Inc.
1.0900
-1.80%
HOTH Hoth Therapeutics, Inc.
0.6289
-10.62%
BSGM BioSig Technologies, Inc.
0.3320
-8.39%
VBIV VBI Vaccines Inc.
0.0629
-33.09%